Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology

被引:139
作者
Portelius, Erik [1 ,2 ]
Olsson, Bob [1 ,2 ]
Hoglund, Kina [1 ,2 ]
Cullen, Nicholas C. [1 ]
Kvartsberg, Hlin [1 ]
Andreasson, Ulf [1 ,2 ]
Zetterberg, Henrik [1 ,2 ,3 ,4 ]
Sandelius, Asa [1 ]
Shaw, Leslie M. [5 ]
Lee, Virginia M. Y. [5 ]
Irwin, David J. [6 ]
Grossman, Murray [6 ]
Weintraub, Daniel [7 ,8 ,9 ]
Chen-Plotkin, Alice [6 ]
Wolk, David A. [6 ]
McCluskey, Leo [6 ]
Elman, Lauren [6 ]
McBride, Jennifer [5 ]
Toledo, Jon B. [5 ,10 ]
Trojanowski, John Q. [5 ]
Blennow, Kaj [1 ,2 ]
机构
[1] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, S-43180 Molndal, Sweden
[2] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden
[3] UCL Inst Neurol, Dept Mol Neurosci, Queen Sq, London WC1E 6BT, England
[4] UK Dementia Res Inst, London WC1E 6BT, England
[5] Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Dept Pathol & Lab Med,Inst Aging, Philadelphia, PA 19104 USA
[6] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA
[7] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA
[8] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA USA
[9] Philadelphia Vet Affairs Med Ctr, MIRECC, Philadelphia, PA USA
[10] Houston Methodist Hosp, Dept Neurol, Houston, TX USA
基金
瑞典研究理事会; 欧洲研究理事会; 美国国家卫生研究院;
关键词
Alzheimer's disease; Neurogranin; Biomarker; Neuropathology; Cerebrospinal fluid; ALZHEIMERS ASSOCIATION GUIDELINES; AMYOTROPHIC-LATERAL-SCLEROSIS; REVISED DIAGNOSTIC-CRITERIA; PRIMARY PROGRESSIVE APHASIA; PROTEIN-KINASE-C; NATIONAL INSTITUTE; MICROGLIAL ACTIVATION; COGNITIVE DECLINE; SYNAPSE LOSS; HUMAN BRAIN;
D O I
10.1007/s00401-018-1851-x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Neurogranin (Ng) is a post-synaptic protein that previously has been shown to be a biomarker for synaptic function when measured in cerebrospinal fluid (CSF). The CSF concentration of Ng is increased in Alzheimer's disease dementia (ADD), and even in the pre-dementia stage. In this prospective study, we used an enzyme-linked immunosorbent assay that quantifies Ng in CSF to test the performance of Ng as a marker of synaptic function. In 915 patients, CSF Ng was evaluated across several different neurodegenerative diseases. Of these 915 patients, 116 had a neuropathologically confirmed definitive diagnosis and the relation between CSF Ng and topographical distribution of different pathologies in the brain was evaluated. CSF Ng was specifically increased in ADD compared to eight other neurodegenerative diseases, including Parkinson's disease (p < 0.0001), frontotemporal dementia (p < 0.0001), and amyotrophic lateral sclerosis (p = 0.0002). Similar results were obtained in neuropathologically confirmed cases. Using a biomarker index to evaluate whether CSF Ng contributed diagnostic information to the core AD CSF biomarkers (amyloid beta (A beta), t-tau, and p-tau), we show that Ng significantly increased the discrimination between AD and several other disorders. Higher CSF Ng levels were positively associated with greater A beta neuritic plaque (Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque score, p = 0.0002) and tau tangle pathology (Braak neurofibrillary tangles staging, p = 0.0007) scores. In the hippocampus and amygdala, two brain regions heavily affected in ADD with high expression of Ng, CSF Ng was associated with plaque (p = 0.0006 and p < 0.0001), but not with tangle, alpha-synuclein, or TAR DNA-binding protein 43 loads. These data support that CSF Ng is increased specifically in ADD, that high CSF Ng concentrations likely reflect synaptic dysfunction and that CSF Ng is associated with beta-amyloid plaque pathology.
引用
收藏
页码:363 / 376
页数:14
相关论文
共 56 条
[1]   Criteria for the diagnosis of corticobasal degeneration [J].
Armstrong, Melissa J. ;
Litvan, Irene ;
Lang, Anthony E. ;
Bak, Thomas H. ;
Bhatia, Kailash P. ;
Borroni, Barbara ;
Boxer, Adam L. ;
Dickson, Dennis W. ;
Grossman, Murray ;
Hallett, Mark ;
Josephs, Keith A. ;
Kertesz, Andrew ;
Lee, Suzee E. ;
Miller, Bruce L. ;
Reich, Stephen G. ;
Riley, David E. ;
Tolosa, Eduardo ;
Troester, Alexander I. ;
Vidailhet, Marie ;
Weiner, William J. .
NEUROLOGY, 2013, 80 (05) :496-503
[2]  
BertoniFreddari C, 1996, ANAL QUANT CYTOL, V18, P209
[3]   Synaptic pathology in Alzheimer's disease: Relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele [J].
Blennow, K ;
Bogdanovic, N ;
Alafuzoff, I ;
Ekman, R ;
Davidsson, P .
JOURNAL OF NEURAL TRANSMISSION, 1996, 103 (05) :603-618
[4]  
Bogdanovic N., 2002, Brain Aging, V2, P18
[5]   NEUROPATHOLOGICAL STAGING OF ALZHEIMER-RELATED CHANGES [J].
BRAAK, H ;
BRAAK, E .
ACTA NEUROPATHOLOGICA, 1991, 82 (04) :239-259
[6]   Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry [J].
Braak, Heiko ;
Alafuzoff, Irina ;
Arzberger, Thomas ;
Kretzschmar, Hans ;
Del Tredici, Kelly .
ACTA NEUROPATHOLOGICA, 2006, 112 (04) :389-404
[7]   Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis [J].
Brettschneider, Johannes ;
Libon, David J. ;
Toledo, Jon B. ;
Xie, Sharon X. ;
McCluskey, Leo ;
Elman, Lauren ;
Geser, Felix ;
Lee, Virginia M. -Y. ;
Grossman, Murray ;
Trojanowski, John Q. .
ACTA NEUROPATHOLOGICA, 2012, 123 (03) :395-407
[8]  
Davidsson P, 1999, ELECTROPHORESIS, V20, P431
[9]   A QUANTITATIVE MORPHOMETRIC ANALYSIS OF THE NEURONAL AND SYNAPTIC CONTENT OF THE FRONTAL AND TEMPORAL CORTEX IN PATIENTS WITH ALZHEIMERS-DISEASE [J].
DAVIES, CA ;
MANN, DMA ;
SUMPTER, PQ ;
YATES, PO .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1987, 78 (02) :151-164
[10]   SYNAPSE LOSS IN FRONTAL-CORTEX BIOPSIES IN ALZHEIMERS-DISEASE - CORRELATION WITH COGNITIVE SEVERITY [J].
DEKOSKY, ST ;
SCHEFF, SW .
ANNALS OF NEUROLOGY, 1990, 27 (05) :457-464